<DOC>
	<DOC>NCT00569842</DOC>
	<brief_summary>Currently, there is no accurate way of predicting the occurrence of Graft vs Host Disease (GvHD) or infection. The purpose of this study is to analyze blood with the ImmuKnow® Assay to see if doctors can detect which patients are at risk for GvHD and for getting an infection before they occur.</brief_summary>
	<brief_title>Investigation of the Cylex® ImmuKnow® Assay</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<mesh_term>Anemia, Aplastic</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<criteria>Patients who are undergoing allogeneic HSCT using a myeloablative preparative regimen for any of the following disorders are eligible: 1. Acute leukemia 2. NonHodgkin's Lymphoma 3. Chronic lymphocytic leukemia 4. Hodgkin's disease 5. Multiple myeloma 6. Myelodysplastic Syndromes 7. Myeloproliferative Disorders 8. Aplastic Anemia 9. Chronic myelogenous leukemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>